Multiple myeloma natural history

Revision as of 14:33, 17 September 2015 by Haytham Allaham (talk | contribs)
Jump to navigation Jump to search

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma natural history

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma natural history

CDC on Multiple myeloma natural history

Multiple myeloma natural history in the news

Blogs on Multiple myeloma natural history

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

A number of organ systems are commonly involved in multiple myeloma including renal failure, hematologic complications, infections, bony and neurological complications; the most common of which being bone pain usually involving the spine and the ribs. Bone involvement leads to pathological fractures and resultant hypercalcemia. Infections such as pneumonias and pyelonephritis are also common complications of multiple myeloma. Renal failure from hypercalcemia and Bence Jones protein filtration, anemia from suppressed bone marrow production and neurological symptoms from brain metastasis are also prominent. According to a report published by National Cancer Institute there is a 43.25 chance of 5 year survival.[1]

Natural History

Prognosis

The average survival of multiple myeloma patients is approximately 3 years and approximately 43.5% of patients survive after 5 years.

The International Staging System can help to predict survival, with a median survival of 62 months for stage 1 disease, 45 months for stage 2 disease, and 29 months for stage 3 disease.

Cytogenetic analysis of multiple myeloma cells may be of prognostic value, with deletion of chromosome 13, non-hyperdiploidy and the balanced translocations t(4;14) and t(14;16) conferring a poorer prognosis. The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.

Prognostic markers such as these are always generated by retrospective analyses, and it is likely that new treatment developments will improve the outlook for those with traditionally 'poor-risk' disease.

Complications

Shown below is a list of common complications associated with multiple myeloma. These include both those caused due to local effects as well as due to distant metastasis and organ damage.[2]

  • Anemia
  • Bone marrow failure
  • Bleeding disorders
  • Infections
  • Bone complications
  • Neurologic complications

References

  1. "Myeloma - SEER Stat Fact Sheets". Retrieved 17 February 2014.
  2. Bladé, J.; Rosiñol, L. (2007). "Complications of multiple myeloma". Hematol Oncol Clin North Am. 21 (6): 1231–46, xi. doi:10.1016/j.hoc.2007.08.006. PMID 17996596. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources